Personalizing cancer treatments for the youngest of patients

December 18, 2013 by Michele Fisher

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. Many of these targeted cancer therapies, however, have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

"Precision medicine constitutes a different method of identifying best treatment options for patients. Instead of prescribing therapy based solely on the organ where the cancer originated, clinicians utilize for a more comprehensive approach. Through a rapid gene sequencing test, the tiniest details of a tumor biopsy are uncovered, sometimes revealing one or more mutations in the patient's genes. It is the mutations themselves that can be targeted with new or existing drugs.

At the Cancer Institute of New Jersey, a team of physician-scientists, bioinformatics specialists, systems biologists, pathologists and a host of others meets weekly to discuss profiling results and determine therapy options. Currently, a genomic analysis clinical trial at the Cancer Institute is focused on those patients with rare or poor-prognosis cancers, including pediatric patients. It is the youngest of patients that Sherrie and Michael Wells, founders of Hugs for Brady, have focused their efforts and are hoping to help with their gift.

"The Kendall Park couple is no stranger to the work being done and care being provided at the Cancer Institute. Their son Brady Michael was treated there for acute undifferentiated leukemia before his passing in 2010, a few weeks shy of his second birthday. It was shortly after that they created the foundation with an aim of comforting children faced with cancer and providing resources to advance research in pediatric cancers and blood disorders.

Hugs for Brady founders Sherrie and Michael Well with Shridar Ganesan in his Rutgers Cancer Institute of New Jersey laboratory. Credit: Matt Rainey

Demonstrating its commitment to research, last year the foundation established the Hugs for Brady Foundation Pediatric Young Investigator Award at the Cancer Institute. The purpose of the two-year grant is to foster the early career development of promising young scientists while they pursue innovative research.

While pediatric cancer survivor rates are generally high, there are those children – like Brady – who unfortunately lose their fight due to rare forms of the disease. Hugs for Brady is committed to helping scientists further unlock the mysteries of rare pediatric cancers. By supporting the cutting-edge research and expert analysis being conducted through the precision medicine initiative at Rutgers Cancer Institute of New Jersey, we are moving closer to a cure," said Sherrie Wells.

"Recent research shows that more potential targets are being identified through genomic analysis for pediatric cancers. The commitment put forth by Hugs for Brady will help Cancer Institute investigators further build on those findings so that optimal treatments can be found for these young patients," said Shridar Ganesan, associate director for translational science at the Cancer Institute, who is the lead investigator of the genomic analysis trial and an associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School. "We are grateful to the Hugs for Brady Foundation for its continued dedication to the fight against pediatric cancer."

Explore further: Next-generation sequencing test identified potential targets for pediatric cancer treatments

Related Stories

Next-generation sequencing test identified potential targets for pediatric cancer treatments

November 5, 2013
A comprehensive genomic profiling test using next-generation sequencing has identified genomic alterations in more than half of pediatric cancer samples tested that would give clinicians potential targets on which to base ...

Gene sequencing project finds family of drugs with promise for treating childhood tumor

December 9, 2013
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle ...

Drug delivery system successfully treats deadly ovarian cancer in mice

December 6, 2013
(Medical Xpress)—Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer ...

Systems medicine paves the way for improved treatment for leukemia patients

December 12, 2013
A multi-disciplinary team of researchers at the Institute for Molecular Medicine Finland, FIMM, and the Helsinki University Central Hospital has developed a novel individualized systems medicine (ISM) strategy which enables ...

Major cancer genotyping study logs 5,000th tumor profile

September 12, 2013
More than 5,000 genetic profiles of tumor DNA have been completed in a large research study by scientists at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital designed to speed the ...

Zebrafish shown to be useful tool in prostate cancer stem cell research

November 7, 2013
(Medical Xpress)—Research from Rutgers Cancer Institute of New Jersey demonstrates that using zebrafish to identify self-renewing tumor stem cells in prostate cancers may be more beneficial than using traditional experimental ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.